Pediatric Clinical Trials Market to reach US$26.47 Billion by 2032;  Phase II Trials to comprise 1/3rd of Global Market Share: FMI Study

Pediatric Clinical Trials Market to reach US$26.47 Billion by 2032; Phase II Trials to comprise 1/3rd of Global Market Share: FMI Study

The pediatric clinical trials market is projected to have a global size of $15.8 billion by 2022, with North America’s share at 45%. The APAC region will account for 25% while the rest comes from elsewhere around the world.

NEWARK, Del., June 16, 2022 /PRNewswire/ — During the forecast period 2022-2032, the pediatric clinical trials market is expected to grow at a value of 5.3%, according to Future Market Insights. In 2021, this market was predicted to have a global valuation of $15 Billionand is expected to reach a sum of US$ 26.47 Billion by 2032. The market is going to face increasing demand owing to the increase of pediatric chronic and genetic diseases all across the world.

FMI Logo

The growing need for novel vaccines and biopharmaceuticals to treat infectious diseases such as measles, polio, tuberculosis, rubella, influenza, mumps, whooping cough, malaria, chickenpox, and staphylococcus pharyngitis is expected to drive market growth. At the same time, diabetes is a big worry among today’s children. The market is being driven by a rising parental awareness of children clinical trials for severe infections and diseases, as well as a large number of CROs doing pediatric research.

Request a Sample PDF @

In 2021, the oncology therapeutic field category had the world’s second-largest revenue share. Cancer is the top cause of death in the globe. Cancer cases in children under the age of 19 are anticipated to reach 291,000 by 2040. With the increasing number of pediatric cancer cases worldwide, many hospitals and institutes are focusing on the development of therapeutic drugs, resulting in an increase in the number of pediatric clinical trials globally.

Irrespective of all these growth factors, the global market for pediatric clinical trials can be hindered for some specific reasons. The high rate of pediatric clinical trial discontinuation for a number of reasons is expected to impede growth in the pediatric clinical trials market. Pediatric studies have a high failure rate due to reasons such as patient enrollment. Other concerns include behavioral disorders and trial conduct issues such as inappropriate dosing, difficulty, and informative termination, as well as regulatory challenges and pharmaceutical toxicity during clinical investigations.

Leading Companies Profiled in Pediatric Clinical Trials Market are

  • Synteract

  • ICON Plc.

  • Syneos Health

  • Medspace, Inc

  • PPD Inc.

  • Premier Research

  • LabCorp Drug Development

  • QPS Holding

  • Pfizer Inc.

  • The Emmes Company, LLC

  • IQVIA Inc.

For critical insights, request for PDF Brochure @

Key Takeaways from the Market Study

  • In 2022, the global pediatric clinical trials market is estimated to have a global market size of US$ 15.8 Billion

  • The pediatric clinical trials market in North America to acquire 45% of the global market share

  • APAC projected to acquire 25% of the global market share

  • By phase, the phase II clinical trials segment took over 33% of the global pediatric clinical trials market share

  • By study design, the treatment studies for clinical trials acquired 66% of the global market share

  • By therapeutic area, the oncology therapeutic area segment acquired almost 17% of the global market share

“The rising prevalence of chronic and hereditary diseases in children is driving this market to conduct more studies to improve treatment efficiency. Simultaneously, many clinical trials for COVID-19 vaccinations for children are being done, which is predicted to greatly increase market development.” comments a Future Market Insights analyst.

Key Segments Covered in the Pediatric Clinical Trials Market Report

Pediatric Clinical Trials Market by Phase Type:

  • Phase I Pediatric Clinical Trials

  • Phase II Pediatric Clinical Trials

  • Phase III Pediatric Clinical Trials

  • Phase IV Pediatric Clinical Trials

Pediatric Clinical Trials Market by Study Design:

Pediatric Clinical Trials Market by Therapeutic Areas:

  • Pediatric Clinical Trials for Infectious Diseases

  • Pediatric Clinical Trials for Oncology

  • Pediatric Clinical Trials for Autoimmune/Inflammatory Diseases

  • Pediatric Clinical Trials for Respiratory Disorders

  • Pediatric Clinical Trials for Mental Health Disorders

  • Pediatric Clinical Trials for Other Therapeutic Areas

Pediatric Clinical Trials Market by Region:

  • North American Pediatric Clinical Trials Market

  • Europe Pediatric Clinical Trials Market

  • Asia Pacific Pediatric Clinical Trials Market

  • Middle East & African Pediatric Clinical Trials Market

  • Latin America Pediatric Clinical Trials Market

Get Customization on this Report for Specific Country @

Competitive Landscape

The industry analyzed is consolidated due to the sheer existence of a few key competitors in the market, with very few extra participants. Market participants’ key strategies included trial initialization, acquisitions, and collaborations.

  • In March 2022, Pfizer initiated a Phase 2/3 study for PAXLOVID tablets, which are specifically designed to treat COVID-19 in young patients. PAXLOVID reduced the risk of hospitalization or death from any cause by 89 percent (within three days of symptom onset) and 88 percent (within five days of appearance of symptoms).

  • In April 2021Novartis announced plans to initiate SMART, a Phase 3b clinical trial to examine the safety and efficacy of Zolgensma (onasemnogene abeparvovec) in young children with spinal muscular atrophy.

More Valuable Insights

Future Market Insights, in its new offering, presents an unbiased analysis of the global pediatric clinical trials market, presenting historical analysis from 2017 to 2021 and forecast statistics for the period of 2022-2032.

The study reveals essential insights on the basis of By Phase (Phase II, IV), By Study Design (Treatment, Observational Studies), By Therapeutic areas (Infectious Diseases, Oncology, Autoimmune/Inflammatory Diseases, Respiratory Disorders, Mental Health Disorders) and Region (North America, South America, Europe, Asia Pacific and Middle East & Africa).

Inquire Before Buying This Research Report @

About the Healthcare Division at Future Market Insights

The healthcare team at Future Market Insights offers expert analysis, time efficient research, and strategic recommendations with an objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 million+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis on key trends including competitive landscape, profit margin, and research development efforts.

About Future Market Insights (FMI)

Future Market Insights (ESOMAR certified market research organization and a member of the Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments based on Source, Application, Sales Channel and End-Use over the next 8-years.


Future Market Insights, Inc
Christiana Corporate,
200 Continental Drive,
Suite 401, Newark,
Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries:
Explore all the latest reports:
LinkedIn| Twitter| Blogs




View original content: sui-13rd-of-global-market-share-fmi-study-301569589.html

SOURCE Future Market Insights

Leave a Comment

Your email address will not be published.